NCT05997927View on ClinicalTrials.gov

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions
Moderate to Severe Atopic Dermatitis
Interventions
DRUG

VC005 tablets

VC005 groups repeat administration for 12 weeks

DRUG

VC005 Tablets Placebo

VC005 placebo groups repeat administration for 12 weeks

Trial Locations (1)

210042

Chinese Academy of Medical Sciences Hospital for Skin Diseases, Nanjing

All Listed Sponsors
lead

Jiangsu vcare pharmaceutical technology co., LTD

INDUSTRY